

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAPLUS - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005
NEWS 18 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 19 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:12:42 ON 27 DEC 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:12:47 ON 27 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

DICTIONARY FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10821793\Struc 1.str



chain nodes :

6 7 8 9 10 11 12 18 19 20 21 22 23 24

ring nodes :

1 2 3 4 5 13 14 15 16 17

chain bonds :

5-6 6-7 6-21 7-8 8-9 9-10 9-22 10-11 11-12 12-13 12-23 17-18 18-19
18-24 19-20

ring bonds :

1-2 1-5 2-3 3-4 4-5 13-14 13-17 14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-21 7-8 9-10 9-22 10-11 12-13 12-23 13-14
13-17 14-15 15-16 16-17 18-19 18-24 19-20

exact bonds :

5-6 8-9 11-12 17-18

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 12:13:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 8 TO 329

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 12:13:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 169 TO ITERATE

100.0% PROCESSED 169 ITERATIONS
SEARCH TIME: 00.00.01

11 ANSWERS

L3 11 SEA SSS FUL L1

=> file caplus medline

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 12:13:11 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:13:11 ON 27 DEC 2005

=> l3

L4 4 L3



=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 4 DUP REM L4 (0 DUPLICATES REMOVED)

=> d abs ibib hitstr 1-4

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
GI




AB The invention relates to compds. I [Ar is a 5- to 10-membered aromatic ring having up to 4 heteroatoms O, S, NH, SO and SO2, in which 1-3 ring atoms

are optionally substituted; R1, R2 are independently (un)substituted (hetero)alkyl, cycloalk(en)yl, cycloalk(en)yl-, aryl- or heteroaryl-(hetero)alkyl; R3, R3' are independently H, (un)substituted alkyl, halo-, sulfhydryl- or hydroxyalkyl, Ph or benzyl; or R3R3' is a ring; R4, R4' are independently H, (un)substituted (hetero)alkyl, cycloalkyl(hetero)alkyl, aryl or heterocyclyl; W is COCOR6, COCO2R6, COCONR62 (R6 is H, alkyl, (hetero)aryl, etc.) or a boryl group; T is alkyl, (hetero)aryl or (hetero)alkyl that inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. The invention further relates to processes for preparing these compds. and to pharmaceutical compns. containing them. Thus, peptide II was prepared via peptide coupling reactions in solution and shown to have HCV NS3-NS4A protease inhibitory activity ($K_i < 0.1 \mu\text{M}$ and $\text{IC}_{50} < 0.5 \mu\text{M}$).



ACCESSION NUMBER: 2005:347009 CAPLUS
 DOCUMENT NUMBER: 142:411657
 TITLE: Preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
 INVENTOR(S): Perni, Robert B.; Court, John J.; Britt, Shawn D.; Pitlik, Janos; Van Drie, John H.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 150 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035525	A2	20050421	WO 2004-US29093	20040907
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005137139	A1	20050623	US 2004-936450	20040907
PRIORITY APPLN. INFO.:			US 2003-500670P	P 20030905
OTHER SOURCE(S):	MARPAT 142:411657			
IT 850251-11-5P				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease)			
RN 850251-11-5 CAPLUS				
CN	L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-4-(1-naphthalenyloxy)-, (4R)-(9CI) (CA INDEX NAME)			

Absolute stereochemistry.



L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
GI



II

AB The invention relates to compds. I [the R groups are H (except R1, R3) or various groups, i.e., R5, R5' are alkyl, halo-, mercapto- or hydroxyalkyl, (un)substituted Ph or benzyl or R5/R5' may form a ring; R2, R4, R7 are (un)substituted alkyl, cycloalkylalkyl or arylalkyl; R1, R3 are (un)substituted alkyl, cycloalkyl, cycloalkylalkyl, etc.; R9, R9', R10, R10' are -X-Y-Z, where X is a bond, alkylene, O, S or imino, Y is a bond, CH2, CO, COCO, SO, SO2 or sulfinylimino, Z is H, alkyl, aryl, etc.; V is CO, SO or SO2, R is CO, SO, SO2, imino, O or a bond; T is alkyl, aryl, etc; W is an acyl or boryl group] or their pharmaceutically-acceptable salts that inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Thus, peptide II was prepared by

peptide coupling reactions in solution and showed K_i in the range 0.5-1 μM for inhibition of HCV.

ACCESSION NUMBER: 2004:902372 CAPLUS
 DOCUMENT NUMBER: 141:350404
 TITLE: Preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
 INVENTOR(S): Farmer, Luc J.; Perni, Robert P.; Bhisetti, Govinda Rao; Wilson, Keith P.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092162	A1	20041028	WO 2004-US11012	20040409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004018986	A1	20040129	US 2003-412600	20030411
CA 2521678	AA	20041028	CA 2004-2521678	20040409
US 2005090450	A1	20050428	US 2004-821793	20040409
PRIORITY APPLN. INFO.:			US 2003-412600	A 20030411
			US 2003-513765P	P 20031023
			US 2002-371846P	P 20020411
			WO 2004-US11012	W 20040409

OTHER SOURCE(S): MARPAT 141:350404

IT 777087-23-7P 777087-37-3P 777087-38-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease)

RN 777087-23-7 CAPLUS

CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-L-valyl-N-[1-[(cyclopropylamino)oxoacetyl]butyl]-3-ethyl-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777087-37-3 CAPLUS

CN L-Prolinamide, 1H-imidazole-2-carbonyl- (2S)-2-cyclohexylglycyl-3-methyl-L-valyl-3-cyclohexyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777087-38-4 CAPLUS

CN L-Prolinamide, 1H-imidazole-2-carbonyl- (2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-3-(1-methylethyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AB The invention discloses peptidomimetic compds. which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compds. of the invention have a bridged bicyclic moiety at the P2 position. The invention further discloses compns. comprising these compds., either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also discloses methods of treating an HCV infection in a patient by administering a composition comprising a compound of the invention. Preparation of compds. of the invention is described.

ACCESSION NUMBER: 2003:58112 CAPLUS

DOCUMENT NUMBER: 138:117634


TITLE: Bridged bicyclic peptidomimetic serine protease inhibitors, and use as antiviral agents against hepatitis C virus

INVENTOR(S): Farmer, Luc; Pitlik, Janos; Perni, Robert; Courtney, Lawrence; Van Drie, John

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006490	A1	20030123	WO 2002-US22027	20020711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449504	AA	20030123	CA 2002-2449504	20020711
US 2003119752	A1	20030626	US 2002-193048	20020711
US 6909000	B2	20050621		
EP 1404704	A1	20040407	EP 2002-749965	20020711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE				
CN 1525979	A	20040901	CN 2002-813816	20020711
JP 2005522409	T2	20050728	JP 2003-512260	20020711
ZA 2003009156	A	20050527	ZA 2003-9156	20031125
NO 2004000127	A	20040311	NO 2004-127	20040112
PRIORITY APPLN. INFO.:				
			US 2001-304615P	P 20010711
			US 2001-322714P	P 20010917
			WO 2002-US22027	W 20020711
OTHER SOURCE(S): MARPAT 138:117634				
IT 488781-08-4 488781-09-5				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (bridged bicyclic peptidomimetic serine protease inhibitors, and use as antiviral agents against hepatitis C virus)				
RN 488781-08-4 CAPLUS				
CN 2-Azabicyclo[2.2.1]heptane-3-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2- cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[oxo[(1S)-1- phenylethyl]amino]acetyl]butyl]-, (1R,3S,4S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 488781-09-5 CAPLUS

CN 2-Azabicyclo[2.2.1]heptane-3-carboxamide, 1H-imidazole-2-carbonyl- (2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
GI

AB Peptidomimetic compds. R9-L- (NR8-R7-CO)nNR6-R5-CO-NX-CONR4-R3-CO-R-CONR1R2
[R is a bond or CF₂; R1 is H, (un)substituted an aliphatic, cyclic, or aromatic
group; R2, R9 are (un)substituted aliphatic, cyclic, or aromatic groups; R3,
R5,
R7 are (un)substituted 1,1- or 1,2-cycloalkylene or -heterocyclylene,
methylene or ethylene; R4, R6, R8 and R10 are H or an optionally
substituted aliphatic group; NX is an (un)substituted cyclic azaheterocyclyl
or azaheterocyclenyl having the unsatn. in the ring distal to ring bearing
the -R5-C(O)-N moiety and to which the -CONR4- moiety is attached; L is
CO, O2C, NR10CO, SO2, or NR10SO2; n is 0 or 1] or pharmaceutically
acceptable salts or prodrugs were prepared for use as protease inhibitors,
particularly as hepatitis C NS3 protease inhibitors. Also provided are
pharmaceutical combinations comprising, in addition to one or more HCV serine
protease inhibitors, one or more interferons exhibiting anti-HCV activity
and/or one or more compds. having anti HCV activity and a pharmaceutically
acceptable carrier. Thus, compd I was prepared and assayed for HCV serine
protease inhibitory activity in combination with interferons. When used
as a single drug treatment, I exhibits an IC50 of 0.48 μ M and
interferon- α 2B is 2.19 U.

ACCESSION NUMBER:	2002:171885	CAPLUS
DOCUMENT NUMBER:	136:232547	
TITLE:	Preparation of peptidomimetic protease inhibitors	
INVENTOR(S):	Babine, Robert Edward; Chen, Shu Hui; Lamar, Jason Eric; Snyder, Nancy June; Sun, Xicheng David; Tebbe, Mark Joseph; Victor, Frantz; Wang, Q. May; Yip, Yvonne Yee Mai; Collado, Ivan; Garcia-Paredes, Cristina; Parker, Raymond Samuel, III; Jin, Ling; Guo, Deqi; Glass, John Irvin	
PATENT ASSIGNEE(S):	Eli Lilly and Company, USA	
SOURCE:	PCT Int. Appl., 424 pp.	
	CODEN: PIXXD2	
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	
FAMILY ACC. NUM. COUNT:	1	
PATENT INFORMATION:		

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018369	A2	20020307	WO 2001-US26008	20010831
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,			

KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

CA 2419607	AA	20020307	CA 2001-2419607	20010831
AU 2001088318	A5	20020313	AU 2001-88318	20010831
EP 1320540	A2	20030625	EP 2001-968040	20010831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517047	T2	20040610	JP 2002-523884	20010831
BR 2001013666	A	20050927	BR 2001-13666	20010831
NO 2003000928	A	20030416	NO 2003-928	20030227
ZA 2003001641	A	20040621	ZA 2003-1641	20030227
US 2005197299	A1	20050908	US 2004-344112	20041217
PRIORITY APPLN. INFO.:			US 2000-229398P	P 20000831
			US 2001-277641P	P 20010321
			WO 2001-US26008	W 20010831

OTHER SOURCE(S): MARPAT 136:232547

IT 402957-63-5P 402957-89-5P 402957-90-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of peptidomimetic protease inhibitors)

RN 402957-63-5 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl- (2S)-2-
 cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]b
 utyl]-4,4-difluorooctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402957-89-5 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1-methyl-1H-imidazole-2-carbonyl- (2S)-
 2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-
 [(cyclopropylamino)oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 402957-90-8 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl- (2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 402960-13-8P 402960-14-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptidomimetic protease inhibitors)

RN 402960-13-8 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1-(phenylmethyl)-1H-imidazole-2-carbonyl- (2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-1-hydroxy-2-oxoethyl]butyl]-4,4-difluorooctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402960-14-9 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl- (2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-1-hydroxy-2-oxoethyl]butyl]-4,4-difluorooctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log h

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

27.49

SINCE FILE

ENTRY

-2.92

TOTAL

SESSION

189.03

TOTAL

SESSION

-2.92

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:23:40 ON 27 DEC 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626